- Home
- MUE vs RCEL Comparison
MUE vs RCEL Comparison
Compare MUE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUE
- RCEL
- Stock Information
- Founded
- MUE 1999
- RCEL N/A
- Country
- MUE United States
- RCEL United States
- Employees
- MUE N/A
- RCEL N/A
- Industry
- MUE Investment Bankers/Brokers/Service
- RCEL Medical/Dental Instruments
- Sector
- MUE Finance
- RCEL Health Care
- Exchange
- MUE Nasdaq
- RCEL Nasdaq
- Market Cap
- MUE 210.6M
- RCEL 227.5M
- IPO Year
- MUE N/A
- RCEL N/A
- Fundamental
- Price
- MUE $9.55
- RCEL $9.21
- Analyst Decision
- MUE
- RCEL Strong Buy
- Analyst Count
- MUE 0
- RCEL 4
- Target Price
- MUE N/A
- RCEL $17.25
- AVG Volume (30 Days)
- MUE 62.6K
- RCEL 201.7K
- Earning Date
- MUE 01-01-0001
- RCEL 05-08-2025
- Dividend Yield
- MUE 4.09%
- RCEL N/A
- EPS Growth
- MUE N/A
- RCEL N/A
- EPS
- MUE N/A
- RCEL N/A
- Revenue
- MUE N/A
- RCEL $64,251,000.00
- Revenue This Year
- MUE N/A
- RCEL $62.33
- Revenue Next Year
- MUE N/A
- RCEL $30.59
- P/E Ratio
- MUE N/A
- RCEL N/A
- Revenue Growth
- MUE N/A
- RCEL 28.14
- 52 Week Low
- MUE $8.53
- RCEL $6.90
- 52 Week High
- MUE $10.17
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- MUE 38.31
- RCEL 56.76
- Support Level
- MUE $9.50
- RCEL $8.15
- Resistance Level
- MUE $9.66
- RCEL $9.36
- Average True Range (ATR)
- MUE 0.20
- RCEL 0.67
- MACD
- MUE -0.02
- RCEL 0.15
- Stochastic Oscillator
- MUE 31.40
- RCEL 93.90
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.